Article Text

other Versions

Randomised controlled trial
Screening for type 2 diabetes does not reduce mortality over 10 years
  1. Marcel C Adriaanse1,
  2. Frans Pouwer2
  1. 1Department of Health Sciences, EMGO Institute for Health and Care Research, VU University Amsterdam, Amsterdam, The Netherlands
  2. 2Department of Medical and Clinical Psychology, Center of Research on Psychology in Somatic diseases (CoRPS), Tilburg University, Tilburg, The Netherlands
  1. Correspondence to: Dr Marcel C Adriaanse
    Department of Health Sciences, EMGO Institute for Health and Care Research, VU University Amsterdam, De Boelelaan 1085, Amsterdam 1081 HV, The Netherlands; marcel.adriaanse{at}

Statistics from

Commentary on: Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 2012;380:1741–8.


Type 2 diabetes is a serious, increasingly common and costly disease. The number of people with diabetes has increased from 153 million in 1980 to 347 million in 2008.1 Effective preventive strategies to reduce the burden of type 2 diabetes and its complications are urgently needed. Population-based screening for type 2 diabetes may be such a strategy. Arguments in favour for diabetes screening are the large percentage of undiagnosed cases, the high-proportion of patients with complications at diagnosis and the long time between onset and diagnosis.2 However, uncertainty persists around the benefit of screening for type 2 diabetes. The …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.